Is mesh better than colporrhaphy for pelvic organ prolapse?

Article

Compared with anterior colporrhaphy, a trocar-guided transvaginal polypropylene mesh repair kit for prolapse of the anterior vaginal wall results in higher short-term success rates, but also higher rates of surgical complications and postoperative events, according to study findings.

Compared with anterior colporrhaphy, a trocar-guided transvaginal polypropylene mesh repair kit for prolapse of the anterior vaginal wall (cystocele) results in higher short-term success rates, but also higher rates of surgical complications and postoperative adverse events, according to the findings of a multicenter, parallel-group, randomized, controlled trial from Scandinavia.

Researchers from Sweden, Finland, Norway, and Denmark randomly assigned 389 women from 53 clinics to cystocele repair with a mesh kit (the same type used routinely for hernias and incontinence) or to traditional colporrhaphy.

At 1 year, using the Pelvic Organ Prolapse Quantification system, almost twice as many women (60.8%) who were treated with the mesh repair kit were at the anatomical designation of stage 0 (no prolapse) or 1 (position of the anterior vaginal wall more than 1 cm above the hymen) as those who underwent colporrhaphy (34.5%) (absolute difference, 26.3 percentage points; 95% confidence interval [CI], 15.6 to 37.0).

The authors of the study concluded that physicians, in collaboration with their patients, must weigh the risks and benefits of each treatment option.

Altman D, Väyrynen T, Engh ME, Axelsen S, Falconer C, for the Nordic Transvaginal Mesh Group. Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. N Engl J Med. 2011;364(19):1826-1836.

Recent Videos
Transforming cervical cancer protection with the BD Onclarity HPV Assay | Image Credit: linkedin.com
March of Dimes 2024 Report highlights preterm birth crisis | Image Credit: marchofdimes.org
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Related Content
© 2024 MJH Life Sciences

All rights reserved.